Table 2.
Comparison of demographics and baseline characteristics between KRAS mutant/ctDNA negative patients (n = 20) and KRAS mutant/ctDNA positive patients (n = 39).
| ctDNA neg (n = 20) | ctDNA pos (n = 39) | p value | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Gender | |||||
| Male | 13 | 65 | 23 | 59 | 0.65 |
| Female | 7 | 35 | 16 | 41 | |
| Age | |||||
| Median (IQR) | 66.7 (55.5–74.4) | 65.1 (59.2–68.6) | 0.38 | ||
| WHO PS | |||||
| 0 | 10 | 50 | 18 | 46 | 0.78 |
| 1–2 | 10 | 50 | 21 | 54 | |
| MRI T | |||||
| T3a | 1 | 5 | 0 | 0 | 0.01 |
| T3b | 1 | 5 | 6 | 15 | |
| T3c | 13 | 65 | 15 | 38 | |
| T3d | 0 | 0 | 10 | 26 | |
| T4a | 4 | 20 | 3 | 8 | |
| T4b | 1 | 5 | 5 | 13 | |
| MRI EMVI+ | |||||
| No | 9 | 45 | 10 | 26 | 0.13 |
| Yes | 11 | 55 | 29 | 74 | |
| MRI CRM+ | |||||
| No | 11 | 55 | 20 | 51 | 0.79 |
| Yes | 9 | 45 | 19 | 49 | |
| Tumour height | |||||
| At/below lev | 16 | 80 | 22 | 56 | 0.09 |
| Above lev | 4 | 20 | 17 | 44 | |
| MRI N status | |||||
| N0 | 6 | 30 | 15 | 38 | 0.28 |
| N1 | 8 | 40 | 8 | 21 | |
| N2 | 6 | 30 | 16 | 41 | |
| Treatment arm | |||||
| CAPOX | 12 | 60 | 21 | 54 | 0.65 |
| CAPOX-C | 8 | 40 | 18 | 46 | |
Abbreviations: WHO: World Health Organisation; PS: performance status; MRI: magnetic resonance imaging; EMVI: extramural venous invasion; CRM: circumferential resection margin; lev: levator muscles.